Heart drugs tested to stop AFib after TAVR
NCT ID NCT07519161
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether two heart medications, metoprolol and amiodarone, can prevent new-onset atrial fibrillation (AFib) in people who develop minor rhythm issues after transcatheter aortic valve replacement (TAVR). About 198 participants will be randomly assigned to one of the drugs or to observation only. The study will track who develops AFib over 90 days and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metoprolol succinate and amiodarone
What this could lead to
If successful, this could provide a clear drug strategy to prevent atrial fibrillation after TAVR, reducing stroke and hospitalization risk.
What could go wrong
This is a relatively small, early-stage trial (198 people) with no phase designation. Both drugs have known side effects, and the results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••